July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

RegenxBio partners with Neurimmune, expands gene therapy pipeline
RegenxBio Inc. (NASDAQ:RGNX) and Neurimmune AG (Zurich, Switzerland) partnered to develop and commercialize gene therapies that use the former's NAV vectors to deliver antibodies to treat neurodegenerative diseases, starting with tauopathies. Financial terms were not disclosed. RegenxBio separately unveiled a preclinical hereditary angioedema gene therapy that delivers a gene encoding an

Read the full 582 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE